Brief: Oragenics Enters Into Licensing Agreement With The National Research Council Of Canada, To Pursue The Rapid Development Of Next-Generation Sars-Cov-2 Vaccines
27/07/2021 12:24
July 27 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS ENTERS INTO LICENSING AGREEMENT WITH THE
NATIONAL
RESEARCH COUNCIL OF CANADA, TO PURSUE THE RAPID DEVELOPMENT OF
NEXT-GENERATION SARS-COV-2 VACCINES
Source text for Eikon: ID:nBwbXJJXQa
Further company coverage: OGEN.A
((reuters.briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing